tiprankstipranks
Scholar Rock’s Advances in Obesity Management Drugs
Company Announcements

Scholar Rock’s Advances in Obesity Management Drugs

Pick the best stocks and maximize your portfolio:

An update from Scholar Rock Holding (SRRK) is now available.

Scholar Rock Holding Corporation revealed promising results from a preclinical study at the American Diabetes Association’s 84th Scientific Sessions, which demonstrated potential benefits of their drug SRK-439 in combination with GLP-1 receptor agonists for weight management. In a mouse model, SRK-439 not only mitigated lean mass loss during treatment but also reduced fat mass rebound after the cessation of the drug. These findings suggest SRK-439 could offer a healthier body composition for those struggling with obesity. Additionally, the company has started a Phase 2 trial to evaluate the effectiveness of another drug, apitegromab, in preserving lean muscle mass in obese individuals.

For a thorough assessment of SRRK stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyBiotech Alert: Searches spiking for these stocks today
TheFlyScholar Rock price target raised to $45 from $36 at Truist
TheFlyScholar Rock price target raised to $50 from $40 at H.C. Wainwright
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App